Objective: Although the Women's Health Initiative trial suggested that menopausal hormone therapy (HT) does not reduce coronary heart disease mortality overall, subsequent results have suggested that there may be a benefit in younger women. The California Teachers Study questionnaire and mortality data were used to examine whether age modified the association between HT and the relative risk of overall mortality and ischemic heart disease deaths.
N umerous observational studies have suggested an inverse association between menopausal hormone therapy (HT) containing estrogen only (estrogen therapy [ET]) or combined estrogen and progestin (estrogen + progestin therapy [EPT] ) and incidence or death from coronary heart disease (CHD). A 1998 meta-analysis of 25 observational studies reported a 30% lower risk of CHD in ET users and a 34% lower risk in EPT users compared with nonusers. 1 Both current (vs former) use and longer duration of use 2 have been associated with reduced CHD risk. Several biological mechanisms have been proposed for the protective effects of estrogen on CHD risk; the most widely recognized are favorable changes in circulating levels of low-density lipoprotein and high-density lipoprotein. [3] [4] [5] Observational studies have also reported a 20% to 45% decreased risk of all-cause mortality, consisting largely of reductions in cardiovascular mortality among HT users compared with nonusers. [2] [3] [4] 6 However, in contrast, randomized clinical trials have shown no benefit or even an increased risk of CHD incidence with current use of ET or EPT. 5, 7 A meta-analysis of 22 small clinical trials, 8 the Heart and Estrogen-Progestin Replacement Study, 7 and the Women's Health Initiative (WHI) 5, 9 reported no difference in risk of CHD death between women randomized to HT and those randomized to placebo. Analysis of overall mortality in the WHI 10 also found no benefit of ET or EPT.
It has been suspected that the time when a woman begins HT, that is, her age or the time since her menopause, plays a role in the apparent discrepancies between observational study results and those of randomized trials, such as the WHI, with regard to the benefits of HT on CHD incidence or mortality. 10, 11 Two reanalyses of the Nurses' Health Study data 12, 13 have indicated that any benefit of HT on cardiovascular disease is restricted to women who started therapy within 10 years of menopause. Moreover, age at HT randomization seems to modify the effect of HT on risks of overall mortality and CHD incidence 10 in the WHI data as well, and women aged 50 to 59 years when randomized to HT had a reduced risk of mortality overall.
Given these differing findings by age at treatment, we sought to clarify the joint effect of HT and age on all-cause and CHD mortality in the large, prospective California Teachers Study (CTS) cohort. 14 We focused specifically on ischemic heart disease (IHD) deaths, which are, by far, the largest contributor to CHD mortality in the United States, and examined age at current use, prior use, duration of use, and age at first use as modifier of HT effects on the risk of these events.
METHODS

Study population
A detailed description of the CTS has been published previously. 14 Briefly, the CTS is a prospective cohort study of 133,479 current and retired female public school teachers and administrators who participated in the California State Teachers Retirement System and returned a mailed, selfadministered questionnaire in 1995-1996. The baseline questionnaire obtained information on menstrual and reproductive events, use of HT and oral contraceptives, family and personal history of diseases, physical activity, smoking, diet, and alcohol consumption; a validation/calibration study 15 found reasonable agreement between dietary variables measured using the baseline questionnaire and 24-hour recalls for a subsample of the cohort. The study was approved by the institutional review boards at all collaborating institutions.
For this analysis, we determined menopause status based on the first questionnaire self-reports of natural or surgical menopause for all CTS participants. After excluding all women who were premenopausal or of unknown menopause status, we also excluded women who reported a hysterectomy with at least part of an ovary left intact and who were younger than 56 years at baseline. This yielded 77,890 postmenopausal women. From this analytic cohort, we excluded women with incomplete information on ever use of HT (n = 6,004), women older than 94 years at baseline (n = 75), and women with missing data on smoking status (n = 480). We also excluded women who, although meeting all the previously mentioned requirements, were 36 years or younger at baseline (n = 94), leaving 71,237 postmenopausal women for analysis.
Follow-up and outcomes
Women contributed person-days of follow-up beginning on the date they completed the baseline questionnaire and continued until either their date of death or December 31, 2004, whichever occurred earlier. Deaths were identified by annual linkage with California mortality files and the Social Security Administration death file. Cause of death was obtained from the California mortality files and through linkage with the National Death Index. Outcomes evaluated were death from IHD (International Classification of Diseases, 10th Revision, codes I20-I25) and overall mortality (deaths from all causes).
On the baseline questionnaire, participants' current, past, or never use of menopausal estrogen and progestin, information on Premarin dose, age at and years of use were asked. Similar information was collected for other estrogens. This analysis restricts ET to pill or patch use. We collected similar information on progestin use. A later follow-up questionnaire updated information about current use of HT beginning in May 2000.
Statistical analysis
The characteristics of the women were compared by age group and by HT status using t tests for continuous variables and Pearson's W 2 statistics for categorical variables. Multivariable Cox proportional hazard regression models were used to estimate the hazard ratios (HR) and corresponding 95% CIs for the associations between current or past HT use at baseline and all-cause mortality or death from IHD. Age in days was used to define the time scale, 16, 17 with an additional adjustment for age at baseline (categorized as e59, 60-64, 65-69, 70-74, 75-84, or 85-94 y). Left truncation of survival times was dealt with by setting up appropriate age at cohort entry and at exit variables for use in PROC PHREG in SAS (version 9.2; Cary, NC). Follow-up began from the date that the baseline questionnaire was returned until either December 31, 2004, or a woman's date of death, whichever came first. In this analysis, HT status (current user, former user, etc) at baseline was used as a time-independent covariate in the Cox regression. We also performed a time-dependent analysis using data from the later questionnaire. For the time-dependent analysis, if a current user at baseline no longer reported use of hormones on follow-up, then she was treated as a former user in risk sets indexed by deaths occurring later than the date she returned the follow-up questionnaire. In earlier risk sets, she was treated as a current user. Women who did not return the later questionnaire were censored on May 1, 2000, in the timedependent analysis. Otherwise, follow-up was terminated on December 31, 2004.
Models were stratified by race/ethnicity and included the following potential confounders: body mass index (16-G18, 18-G22.5, 22.5-G25, 25-G30, or 30-e54.9 kg/m 2 or missing/ invalid, ie, G16 or 954.9 kg/m 2 ); smoking status (never, past, current); pack-years of smoking (continuous); alcohol consumption (920 g/d, G20 g/d, and past drinkers); recent recreational physical activity (h/wk); total caloric intake; calories from fat, protein, and cholesterol during the year before baseline; and self-reported history of diabetes, high blood pressure, myocardial infarction or heart disease, cancer other than nonmelanoma skin cancer, and stroke (yes/no).
By adding additional terms to the models described previously, we estimated effects for type of HT used, duration of use, age at first use, and years from menopause to first use, using likelihood ratio tests. Type of therapy had five categories: none, ET, EPT, mixed use of ET and EPT, and other/ unknown, including uncategorized hormone use and women reporting no hormone use. In our main statistical analysis, we combined women reporting current use of either ET or EPT into a current HT users category, and we did a similar categorization for past use. In additional analyses, we assessed whether differential effects of HT type (ET only or EPT) were evident.
We included interaction terms to investigate whether age at first use of HT was a modifier of the effects of current or past HT use. We also included interaction terms for age at baseline and current or past HT use to investigate whether age at baseline modified the effect of HT on all-cause mortality and on IHD mortality. The mean age for each age at baseline category was used in the models to test for trend and for linear interactions with HT use. We used Wald tests to assess the age Â HT interactions (specifically, to test the interaction between age at first HT use and current or past HT use). We considered two-sided P values less than 0.05 as statistically significant. All analyses were conducted using SAS (version 9.2).
RESULTS
Baseline characteristics
As expected, the frequency of deaths from all causes and deaths due to IHD over the follow-up period (ranging from 5 to 7 y) rose markedly with increasing age at baseline (Table 1) .
Current HT users were less likely to have a body mass index of 30 kg/m 2 or greater and to be current smokers and more likely to engage in physical activity, be current alcohol drinkers, and consume more calories than never or former HT users ( Table 2 ). Current HT users were less likely to report a history of heart disease and reported a lower baseline prevalence of cancer, stroke, and diabetes than did former or never HT users. As can be seen in Table 1 , however, current HT users were also younger than former or never HT users so that the crude differences shown in Table 2 cannot be interpreted easily without additional age correction such as that provided by Cox regression for the comparisons of mortality outcomes between HT groups.
Hormone use in later follow-up
Of the 37,912 women reporting current HT use at baseline, 24,911 (66%) returned the follow-up questionnaire and provided data on HT use. Of these women, 5,144 (21%) reported no current use of ET or EPT at that time. Of the 33,325 women not reporting current use of HT at baseline, 21,847 (66%) returned the later questionnaire. Continued use of HT was related to age at baseline, with 81% of current users younger than 65 years at baseline reporting continued use at follow-up compared with 69% of current users 75 years or older at baseline.
Mortality during follow-up by HT use
During follow-up, deaths were reported in 18.3% of never users of HT and 17.9% of former users, compared with 6.9% of women currently taking HT at baseline. Fewer deaths from IHD occurred among current HT users (1.0%) than among never (3.7%) or former (3.0%) users. The Cox model (see Methods section) compared the age-specific hazards of mortality by HT status. We found that HT use at baseline was associated with an overall reduction in risk of all-cause and IHD mortality (Tables 3 and 4 ). Women who currently took HT had a hazard of death from all causes that was 0.83 times that of never users (95% CI, 0.79-0.87), and their hazard of death from IHD was 0.84 times that of never users (95% CI, 0.74-0.95). Mortality risk was also lower among former HT users than never users (all-cause mortality HR, 0.88; 95% CI, 0.83-0.93; IHD mortality HR, 0.81; 95% CI, 0.71-0.92).
Effects of HT by age
Age at baseline was a strong modifier of the relationship between current use of HT at baseline and all-cause mortality. For women using HT at baseline, the HRs increased with increasing age category for all-cause mortality (P trend G 0.0001), suggesting that the reduction in relative risk associated with current HT use diminishes as age increases (Table 3) . For women 75 years or older using hormones at baseline, the risk of death was not significantly reduced (age 75-84 y: HR, 1.00; 95% CI, 0.91-1.09; age 85-94 y: HR, 0.94; 95% CI, 0.81-1.10). In contrast to the pattern seen for current use, former use, although significantly protective overall, showed no marked variation in risk of all-cause mortality by age.
For IHD mortality, a similar risk pattern was observed where the marked reduction in risk associated with HT use at baseline declined with increasing age at baseline (P trend = 0.008; Table 4 ). The protective effect of current use was very striking for women 59 years or younger (HR, 0.38; 95% CI, 0.22-0.67) but virtually vanished by age 75 to 84 years (HR, 0.93; 95% CI, 0.77-1.12). As with overall mortality, Cox regression models included age at questionnaire, status of hormone therapy, and their interaction, stratified by race and adjusted for body mass index, smoking, total pack-years, alcohol consumption, physical activity during the past 3 years, dietary intake, other hormone, and prior history of myocardial infarction, stroke, cancer, and diabetes. Overall estimates using previously mentioned models, without interaction between age and hormone therapy. c Test for trend (interaction) using mean age of each group as continuous variable. Cox regression models stratified by race and adjusted for all potential confounders.
former HT use showed no trend in risk of IHD mortality by age (P trend = 0.24).
Additional analyses
Other aspects of HT use that may affect all-cause mortality or IHD mortality, such as formulation (ET vs EPT), duration, age at first use, and years since menopause at first use, were assessed (Tables 5 and 6 ). None of these factors seemed influential (all confidence limits overlapped 1) when added to a model that included status of HT use at baseline and the interaction of this status with age at baseline. Treating HT use as a time-dependent variable, as described in the statistical analysis section, gave results that were both qualitatively and quantitatively extremely similar to those in Tables 3 and 4 .
Summary of results
The risk for all-cause mortality was decreased by 45% or more among women younger than 65 years who reported Cox regression models included age at questionnaire, status of hormone therapy, and their interaction, stratified by race and adjusted for body mass index, smoking, total pack-years, alcohol consumption, physical activity during the past 3 years, dietary intake, other hormone, and prior history of myocardial infarction, stroke, cancer, and diabetes. Overall estimates using previously mentioned models without interaction between age and hormone therapy. c Test for trend (interaction) using mean age of each group as the continuous variable. Cox regression models stratified by race and adjusted for all potential confounders. a HRs for types of hormone, duration of hormone use, age at start of HT, and years from menopause to HT, respectively, when these variables are added to Cox regression models containing terms for age at questionnaire, HT status, and interactions between age and current and former hormone use. Models were adjusted for body mass index, smoking, total pack-years, alcohol consumption, physical activity during past three years, dietary intake, and prior history of myocardial infarction, stroke, cancer, and diabetes and were stratified by race. currently taking HT at baseline compared with similarly aged women who reported no history of HT use. On the other hand, women 75 years or older at baseline who reported currently taking HT were at similar risk of death as never users. The statistical significance of this inverse trend with age in the protective effect of HT was very strong, reflecting both the strength of this trend and the large number of HT users participating in our study. Other variables, such as duration of HT use or age at start of use, were far less significant modifiers of the HT effects than was current age.
For death caused by IHD, we observed the same pattern as for all-cause mortality, with HRs attenuating toward the null with increasing age (P trend = 0.008). Thus, even though the overall risk of IHD mortality was reduced overall by HT, the protective effect weakened considerably with use at older ages.
DISCUSSION
Our results showing an overall reduction in risk of all-cause and IHD mortality with HT use are consistent with those from previous observational studies, but not with those from clinical trials. However, our results for all-cause mortality with HT use by age group were generally comparable with those from the WHI trial, 10 which found decreased risk in women randomized at age 50 to 59 years (HR, 0.70; 95% CI, 0.51-0.96) and increased risk in women randomized at age 70 to 79 years (HR, 1.14; 95% CI, 0.94-1.37). That is, age seems to modify the relationship between HT and mortality both in our study and in the WHI randomized trial, with both studies showing a similar trend of HRs increasing with increasing age. It has been argued that increased risk of CHD among HT users in the WHI clinical trial is probably related to age (or time duration since menopause) at first use of HT. 11, 12 Another explanation is that it is a woman's current age rather than her age at first use that modifies the effect of HT. Because of the relatively short follow-up period and more confined age range for the WHI trial, that study could not differentiate age at randomization from age at current use. In contrast, we were able to estimate the influence of these two age periods separately as modifying variables. Assuming that self-reported baseline HT use reflected a women's usage pattern over the follow-up period (and our data from 2000-2001 indicate that most [79%] of current users of HT at baseline remained current users at that time), our results suggest that it is age at current use that is the important determinant. We found that age at baseline was a more significant modifier of the relationship between HT use at baseline and both all-cause mortality and IHD mortality than was age at or years since menopause and first use. We interpret this finding as evidence that current age, rather than age at first use, is relevant to the reduced hazards of all-cause and IHD mortality. Therefore, the implications of our findings are similar for older women who are current HT users of long duration and for older TABLE 6 . Effects of different types of hormone, duration of hormone use, age at start of HT, and years from menopause to HT use in relation to IHD death women who might be currently considering whether to begin using HT for the first time. Several potential biases, including selection bias, compliance bias, follow-up bias, and inadequate control of confounding, may account for the protective effects of HT use on mortality that have been seen in observational studies. Our study may be subject to the previously described Bhealthy woman effect,[ whereby women taking HT have more education, are of higher social class, are more compliant and healthier, and have a more favorable lifestyle than nonusers do. 1 Education and social class are strongly inversely associated with risk factors for CHD. 18 However, because the participants in our study were all public school teachers or administrators in California, our sample is homogeneous in some characteristics and more uniform with respect to education and socioeconomic status than some other cohorts are. Therefore, it may be probable that education or social class were confounders of the relationship between HT use and risk of death from IHD in our study. The follow-up period for the current analysis includes a span of approximately 2.5 years subsequent to the widely publicized WHI results 9 (mid-2002 to the end of 2004). Based on other studies showing a profound impact of the WHI results on HT use in the general population, 19-21 many CTS participants who reported current HT use at baseline would have ceased using HT by the end of the follow-up period. It seems improbable, however, that cessation of hormone use or any of the aforementioned biases caused the modifying effect of age at baseline observed in this cohort.
An additional concern is that we may have missed shortterm increases in the risk of mortality occurring shortly after the beginning of HT because of left truncation of women who die or are otherwise less likely to participate shortly after a disease event. Hernan et al 13 found increased risk of CHD incidence in the 2 years after start of HT in the data from the Nurses' Health Study by examining a series of nested Bnonrandomized trials[ of CHD disease incidence in HT initiators and noninitiators, over a total of eight contact/recontact cycles, while using time of HT initiation rather than time of questionnaire as the start of observation in these Btrials. [ We are not able to replicate these analyses because we did not obtain CHD incidence for the teachers and are reliant on mortality data. Although missing such short-term events could have led to biased estimates of the overall effect of HT on mortality (Binitiation bias[), we find it improbable that this would have led to the distinct age Â HT interactions that are seen so strongly here. Nor would this issue seem to negate the implications of our findings for older women who started HT close to menopause about whether they now benefit from continued HT use. Our study of the relative importance of the two time-related variables, age at start of HT versus age at baseline, implies that they do not.
A strength of this analysis is the high proportion of CTS participants, even those at a relatively advanced age, who reported current HT use on the baseline questionnaire. This provided considerable statistical power to estimate the effects of use over a wide age range. Furthermore, the broad age distribution of women in the CTS and the wide diversity in ages at first HT use allowed us to address questions about the modifying effects of current age, as distinct from the modifying effect of age at first use.
CONCLUSIONS
In summary, our study suggests that the health consequences of HT vary primarily by age of current use, with age at first use being of negligible independent importance. We found an association between current use at baseline and reduced risk for all-cause mortality in younger, but not older, postmenopausal women in the CTS. Our results add to the growing evidence that hormone use may have a beneficial effect in younger women but have little cardiovascular benefit in older women and have direct implications regarding the lack of potential benefits of continued use of HT for older women who began HT close to menopause.
